Drug Discovery & Development
Plant-microbe biology study uncovers trigger for tumor growth in humans
Targeting the plasminogen-apple-nematode domain can block cell proliferation, pointing to the potential to treat certain cancers, according to a paper published in the journal Communications Biology. Read More
NIH-funded research yields promising results for potential universal flu vaccines
A study funded by the National Institutes of Health (NIH) has shown that a new universal flu vaccine offers broad protection against different strains and subtypes of influenza A virus infections. Read More
Cell and gene therapy sector remains strong despite challenges: ARM CEO
The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry. Read More
Beta cell gene deletion stops type 1 diabetes in mice, suggesting new way to prevent disease
Deleting a proinflammatory gene in the beta cells of pre-diabetic mice stops the development of type 1 diabetes, pointing to a potential way to prevent the condition, according to a study published on June 28 in the journal Cell Reports. Read More
Life sciences industry’s search for talent is becoming more challenging: study
While more professionals are engaged in life sciences research in the U.S. and a record number of people are graduating in the biological and biomedical sciences, the ability of employers to find life sciences research talent is proving extremely difficult, according to a new report from CBRE. Read More
The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have a limited pool of patients, contends Clincierge CEO Scott Gray. He spoke with ScienceBoard.net about Clincierge's study examining the patient experience in clinical trials of rare diseases. Read More
New era of non-viral DNA-delivered gene therapy seen emerging
Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in non-viral DNA-delivered gene therapy, according to Xalud Therapeutics CEO Diem Nguyen, PhD. Read More
Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense technology platform and created one of the largest, most advanced pipelines in the biotech industry. Crooke shared his story in an interview with ScienceBoard.net. Read More
11.7T MR spectroscopy quantifies brain glucose metabolism
French researchers have developed a new MR (magnetic resonance) spectroscopy approach to study brain glucose metabolism, a process significantly involved in Alzheimer's disease. They presented their work in an animal study at the annual meeting of the International Society for Magnetic Resonance in Medicine. Read More
Manufacturing partnerships support high quality cell therapies
Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Read More
Conferences
Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Sales and Marketing Professionals in Science Annual Meeting
September 1
United States
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter